Skip to main content
main-content

Hepatitis B virus

Hepatitis B virus

14-08-2018 | Oncology | News | Article

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

Source:

JAMA Surg 2018; doi:10.1001/jamasurg.2018.2721
JAMA Surg 2018; doi:10.1001/jamasurg.2018.2728

03-08-2018 | HBV | News | Article

HCC risk score developed for patients with chronic hepatitis B virus

Researchers have developed and validated a score for predicting the risk for hepatocellular carcinoma in Asian patients with chronic hepatitis B virus infection who are taking oral antiviral therapy.

Source:

J Hepatol 2018; doi:10.1016/j.jhep.2018.02.032

03-08-2018 | HBV | News | Article

HCC risk remains even after achieving positive HBV outcomes

Two meta-analyses published in the Journal of Viral Hepatitis confirm that patients with hepatitis B virus infection remain at risk for hepatocellular carcinoma even after achieving positive virologic outcomes, and identify factors associated with the risk.

Source:

J Viral Hepat 2018; doi:10.1111/jvh.12928
J Viral Hepat 2018; doi: 10.1111/jvh.12905

03-08-2018 | HBV | News | Article

Editor's pick

Global HBV prevalence estimated at 3.9%

More than 290 million people, or 3.9% of the global population, are infected with hepatitis B virus, and while efforts to combat infection are improving, greater access to diagnosis and treatment is needed to meet global targets, report The Polaris Observatory Collaborators.

Source:

Lancet Gastroenterol Hepatol 2018; 3: 383–403

03-05-2018 | HBV | News | Article

Editor's pick

Updated AASLD guidance released on HBV prevention, diagnosis, and treatment

The American Association for the Study of Liver Diseases has issued a guidance statement for chronic hepatitis B virus, covering topics ranging from screening and prevention through to the clinical management of patients.

Source:

Hepatology 2018; 67: 1560–1599

03-05-2018 | HBV | News | Article

End of treatment HBsAg levels may predict HBV relapse

Hepatitis B surface antigen levels at the end of treatment or prophylaxis with nucleos(t)ide analog inhibitors could be a useful indicator of hepatitis B virus relapse, suggest two Taiwanese studies.

Source:

J Viral Hepat 2018; Advance online publication, J Gastroenterol Hepatol 2018; Advance online publication

03-05-2018 | HBV | News | Article

‘Excellent’ survival with long-term TDF, entecavir treatment of chronic HBV

Caucasian patients with chronic hepatitis B virus infection who receive long-term therapy with tenofovir disoproxil fumarate or entecavir have “excellent” survival, which is comparable to that of the general population, say researchers.

Source:

J Hepatol 2018; Advance online publication

01-02-2018 | HBV | News | Article

Editor's pick

ACP, CDC issue HBV vaccination, screening best practice advice

The American College of Physicians and Centers for Disease Control and Prevention have released best practice guidance for hepatitis B virus vaccination, screening, and linkage to care.

Source:

Ann Intern Med 2017; 167: 794–804

01-02-2018 | HBV | News | Article

Diabetes linked to elevated HCC risk after HBsAg seroclearance

Diabetes remains an independent risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection even after hepatitis B surface antigen seroclearance, findings indicate.

Source:

Clin Gastroenterol Hepatol 2017; Advance online publication

01-02-2018 | HBV | News | Article

Estimates of HBV carrier numbers in Japan released

Japanese researchers have generated a nationwide estimate of total numbers of hepatitis B virus carriers and treated patients in 2011, comparing it with earlier estimates from 2000.

Source:

J Viral Hepat 2017; Advance online publication

22-12-2017 | HBV | News | Article

FIB-4 index identifies chronic HBV patients with lowest HCC risk

The noninvasive fibrosis-4 index can further refine the existing favorable clinical profile for hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B virus infection and help identify those with the lowest risk, say researchers.

Source:

Am J Gastroenterol 2017; 112: 1564–1574

22-12-2017 | HBV | News | Article

Serum HBV RNA may represent noninvasive marker for HBV progression

Serum hepatitis B virus RNA levels correlate with viral transcriptional activity and histologic changes in the livers of patients with chronic HBV who are receiving nucleos(t)ide analog therapy, Chinese researchers report.

Source:

J Hepatol 2017; Advance online publication

15-12-2017 | HBV | News | Article

Durability of HBsAg clearance induced by NA therapy demonstrated

Clearance of hepatitis B surface antigen with nucleos(t)ide analogs is as durable as spontaneous clearance in patients with chronic hepatitis B virus infection, researchers report.

Source:

J Hepatol 2017; Advance online publication

15-12-2017 | HBV | News | Article

Editor's pick

HBV remains major contributor to primary liver cancer globally

Hepatitis B virus infection is the leading cause of incident primary liver cancer and associated mortality worldwide, according to research published in JAMA Oncology.

Source:

JAMA Oncol 2017; 3: 1683–1691
Int J Infect Dis 2017; 65: 15–21

11-12-2017 | HBV | News | Article

Partial TDF responders achieve virologic response with treatment continuation

Most patients with chronic hepatitis B virus infection initially classed as partial responders to treatment with tenofovir disoproxil fumarate achieve a virologic response without additional treatment adjustment, research suggests.

Source:

Dig Dis Sci 2017; 62: 2908–2914

11-12-2017 | HBV | News | Article

HCC, mortality risk remains for untreated immune tolerant-phase HBV patients

Being in the immune tolerant phase of chronic hepatitis B virus (HBV) infection is no assurance against the risk for developing hepatocellular carcinoma (HCC), requiring liver transplantation, or dying, say South Korean investigators.

Source:

Gut 2017; Advance online publication

29-09-2017 | HBV | News | Article

Editor's pick

Consensus reached on design of clinical trials for novel, curative HBV therapies

A panel of hepatitis B virus experts has issued a consensus statement intended to aid in standardizing the efficacy and safety appraisals of novel, potentially curative antiviral and immune modulatory agents.

Source:

Hepatology 2017; 66: 1296–1313, J Hepatol 2017; 67: 847–861

29-09-2017 | HBV | News | Article

Novel indices to diagnose fibrosis in chronic HBV patients developed

Two research groups have developed noninvasive indices to detect significant fibrosis in treatment-naïve patients with chronic hepatitis B virus infection, one using serum levels of Golgi protein 73 and liver stiffness, and the other based on the ratio of gamma-glutamyl transpeptidase to albumin.

Source:

Liver Int 2017; Advance online publication, J Viral Hepat 2017; Advance online publication

26-09-2017 | HBV | News | Article

Sex modifies age-related HCC risk after HBsAg clearance

Achieving hepatitis B surface antigen seroclearance neutralizes the increased risk for hepatitis B virus-related hepatocellular carcinoma among women aged 50 years or younger, but not among older women or men regardless of their age, research indicates.

Source:

J Hepatol 2017; Advance online publication

26-09-2017 | HBV | News | Article

Treatment-induced liver stiffness reduction lowers HCC risk in HBV patients

Achieving a subcirrhotic liver stiffness level after antiviral therapy halves the risk for hepatocellular carcinoma in patients with chronic hepatitis B virus-related advanced fibrosis or cirrhosis, Korean research shows.

Source:

J Gastroenterol Hepatol 2017; Advance online publication

image credits